- Medical news & Guidelines
- Cardiology and CTVS
- Critical Care
- Diabetes and Endocrinology
- Laboratory Medicine
- Health news
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Dadra and Nagar Haveli
- Daman and Diu
- Himachal Pradesh
- Jammu & Kashmir
- Madhya Pradesh
- Tamil Nadu
- Uttar Pradesh
- West Bengal
- Medical Education
PET/CT predicts early response to TARE treatment in liver cancer patients: Study
France: A recent study in the American Journal of Roentgenology has shown that early posttreatment evaluation with PET/CT may help identify six-month response and overall survival (OS) after TARE in hepatocellular carcinoma (HCC) patients. This in turn could result in early adapted therapeutic management.Assessment of the treatment response of HCC after transarterial radioembolization (TARE)...
France: A recent study in the American Journal of Roentgenology has shown that early posttreatment evaluation with PET/CT may help identify six-month response and overall survival (OS) after TARE in hepatocellular carcinoma (HCC) patients. This in turn could result in early adapted therapeutic management.
Assessment of the treatment response of HCC after transarterial radioembolization (TARE) is challenging. This is because the response by conventional imaging criteria may not be evident until after 6 months of the treatment. Though HCC shows variability avidity for FDG, some cases of HCC without avidity for FDG show avidity for 18F-FCH.
To address this challenge, Edouard Reizine, Department of Radiology, APHP, HU Henri Mondor, Creteil, Val-de-Marne, France, and colleagues aimed to evaluate the utility of early posttreatment evaluation by PET/CT using FDG or 18F-FCH to predict 6-month treatment response and survival after TARE in HCC patients in a retrospective study.
The study included (mean age 67 years; 34 men, 3 women) with documented HCC treated by TARE who underwent both pretreatment FDG PET/CT and 18F-FCH PET/CT, as well as early FDG PET/CT and/or 18F-FCH PET/CT 4-8 weeks after treatment. FDG PET/CT and 18F-FCH PET/CT examinations were performed on separate dates. Response assessment by mRECIST on multiphase CT or MRI was performed at one month and six months in 23 patients.
Early PET/CT response and one-month mRECIST response were assessed as predictors of six-month mRECIST response. Univariable and multivariable predictors of overall survival (OS) were identified.
On pretreatment PET/CT, 28 (76%) patients were FDG-positive, 15 (41%) FCH-positive 6 (16%) both FDG-positive and FCH-positive.
Based on the study, the researchers found the following:
- Twelve of 28 FDG-positive HCCs exhibited early response by FDG PET/CT; 7 of 15 FCH-positive HCCs exhibited early response by 18F-FCH PET/CT.
- 52% patients exhibited six-month mRECIST response. Early posttreatment PET/CT response exhibited 100% (12/12) sensitivity and 100% (11/11) specificity for six-month mRECIST response, whereas one-month mRECIST response exhibited 67% (8/12) sensitivity and 100% (11/11) specificity for six-month mRECIST response.
- Early postteatment PET/CT response was a significant independent predictor of OS on univariable (hazard ratio: 0.37) and multivariable analyses (hazard ratio: 0.24).
The researchers concluded, "Early post-TARE evaluation by PET/CT using FDG or 18F-FCH may predict six-month response and OS in patients with HCC."
American Journal of Roentgenology: -. 10.2214/AJR.21.26485
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at firstname.lastname@example.org. Contact no. 011-43720751